Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cross-reactivity

Cross-reactivity

Allergic Reactions

Allergic Reactions

Allergic Drug Reactions

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...

Allergic Reactions: Anaphylaxis

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study.

Scientific reports·2024

Same author

Informing the use of a supplementary immunisation programme for the management of a community cluster of invasive meningococcal disease, Yorkshire, 2022.

Public health·2023

Same author

COVID-19 associated with universities in England, October 2020-February 2022.

Public health·2023

Same author

A protracted outbreak of difficult-to-treat resistant Pseudomonas aeruginosa in a haematology unit: a matched case-control study demonstrating increased risk with use of fluoroquinolone.

The Journal of hospital infection·2022

Same author

An outbreak of hepatitis A virus infection in a secondary school in England with no undetected asymptomatic transmission among students.

Epidemiology and infection·2022

Same author

Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2021

Same journal

AMPK-driven immunometabolic reprogramming enhances CD19<sup>+</sup>CD21<sup>hi</sup>CD24<sup>hi</sup> regulatory B cell-mediated suppression of atopic dermatitis.

The Journal of allergy and clinical immunology·2026

Same journal

Corrigendum.

The Journal of allergy and clinical immunology·2026

Same journal

Comparative Efficacy of Biologic Agents for Severe Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Network Meta-analysis.

The Journal of allergy and clinical immunology·2026

Same journal

Tamoxifen-driven neutrophil reprogramming protects from pulmonary Granulibacter bethesdensis infection in chronic granulomatous disease.

The Journal of allergy and clinical immunology·2026

Same journal

Clinical and transcriptomic characterization of mixed granulocytic COPD phenotype.

The Journal of allergy and clinical immunology·2026

Same journal

Dupilumab outcomes in pediatric asthma by early eosinophil status: post hoc analysis of VOYAGE/EXCURSION.

The Journal of allergy and clinical immunology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 11, 2026

Harvesting Venom Toxins from Assassin Bugs and Other Heteropteran Insects

Harvesting Venom Toxins from Assassin Bugs and Other Heteropteran Insects

Published on: April 21, 2018

Api m 6: a new bee venom allergen.

A Kettner¹, G J Hughes, S Frutiger

¹Institute of Biochemistry, University of Lausanne, Lausanne, Switzerland.

The Journal of Allergy and Clinical Immunology

|May 10, 2001

Summary

This summary is machine-generated.

Researchers identified Api m 6, a new bee venom (BV) allergen, which triggers significant IgE and T-cell responses in allergic patients. This finding is crucial for developing better diagnostics and therapies for bee venom hypersensitivity.

More Related Videos

Basophil Activation Test for Allergy Diagnosis

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

Author Spotlight: Optimizing Scorpion Venom Extraction for Antivenom Production

Author Spotlight: Optimizing Scorpion Venom Extraction for Antivenom Production

Published on: October 6, 2023

Related Experiment Videos

Last Updated: Apr 11, 2026

Harvesting Venom Toxins from Assassin Bugs and Other Heteropteran Insects

Harvesting Venom Toxins from Assassin Bugs and Other Heteropteran Insects

Published on: April 21, 2018

Basophil Activation Test for Allergy Diagnosis

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

Author Spotlight: Optimizing Scorpion Venom Extraction for Antivenom Production

Author Spotlight: Optimizing Scorpion Venom Extraction for Antivenom Production

Published on: October 6, 2023

Area of Science:

Allergen characterization
Immunology
Protein biochemistry

Background:

Understanding allergen structure is key for developing diagnostic and therapeutic tools for allergic diseases.
Bee venom (BV) hypersensitivity affects many individuals, necessitating further research into its causative agents.

Purpose of the Study:

To identify and characterize a novel, low-molecular-weight allergen from bee venom (BV) that binds to IgE antibodies.
To investigate the immunological response elicited by this newly identified allergen.

Main Methods:

Bee venom proteins were fractionated using size exclusion chromatography and High-Performance Liquid Chromatography (HPLC).
IgE binding was assessed via immunoblotting, and T-cell response was measured using proliferation assays.
Amino acid sequencing was performed using Edman degradation and mass spectrometry.

Main Results:

A novel allergen, Api m 6, was identified, recognized by IgE in 42% of bee venom-hypersensitive patients.
Api m 6 induced proliferation in peripheral blood mononuclear cells (PBMCs) from both hypersensitive patients and a control subject.
Four isoforms of Api m 6 were characterized, sharing a common core structure but differing in terminal sequences, with no significant homology to known proteins.

Conclusions:

A new bee venom allergen, Api m 6, has been identified and sequenced.
Api m 6 elicits a robust IgE and T-cell response in a significant portion of bee venom-hypersensitive individuals.
Api m 6 represents a potential target for improved diagnostics and immunotherapy for bee venom allergy.